The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice

Journal of Hepatology

Volumn 57, Issue 1, 2012, Pages 84-91

  Kitamura, Takuya ^a,c   Connolly, Kevin ^a   Ruffino, Lynnsie ^a   Ajiki, Tetsuo ^b   Lueckgen, Aline ^a   DiGiovanni, John ^a,d   Kiguchi, Kaoru ^a,d  

^a UNIVERSITY OF TEXAS   (United States)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Biliary tract cancer; ErbB2; Gallbladder carcinoma; Histone deacetylase

Indexed keywords

ABEXINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; HISTONE; MICRORNA; TUBULIN; VORINOSTAT;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOMICROSCOPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GALLBLADDER CARCINOMA; HISTOLOGY; HISTONE ACETYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BENZOFURANS; CARCINOMA; CARRIER PROTEINS; CELL DIVISION; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; GALLBLADDER; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, MUTANT STRAINS; MUCIN-4; PHOSPHORYLATION; RNA, MESSENGER;

EID: 84862683024     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.01.018     Document Type: Article

References (30)

1. Kiguchi K, DiGiovanni J. Role of growth factor signalling pathways. In: CR Thomas Jr CF, editor. Biliary tract and gallbladder cancer. New York: Demos Medical Publishing, LLC; 2009. p. 19-34.
2. Sirica AE. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol 2008;14:7033-7058.
3. Wiedmann M, Feisthammel J, Bluthner T, Tannapfel A, Kamenz T, Kluge A, et al. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVPAEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 2006;17:783-795.
4. Kim YW, Huh SH, Park YK, Yoon TY, Lee SM, Hong SH. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep 2001;8:1127-1132.
5. Ogo Y, Nio Y, Yano S, Toga T, Koike M, Hashimoto K, et al. Immunohisto-chemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma. Anticancer Res 2006;26:763-770.
6. Sirica AE, Radaeva S, Caran N. NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia. Am J Pathol 1997;151:1685-1694.
7. Kiguchi K, Carbajal S, Chan K, Beltran L, Ruffino L, Shen J, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001;61:6971-6976.
8. Kiguchi K, Ruffino L, Kawamoto T, Ajiki T, Digiovanni J. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res 2005;11:5572-5580.
9. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 2009;277:8-21.
10. Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 2006;5:1309-1317.
11. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, et al. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1985;1:579-596.
12. Warren CM, Krzesinski PR, Greaser ML. Vertical agarose gel electrophoresis and electroblotting of high-molecular-weight proteins. Electrophoresis 2003;24:1695-1702.
13. Riggs PK, Angel JM, Abel EL, DiGiovanni J. Differential gene expression in epidermis of mice sensitive and resistant to phorbol ester skin tumor promotion. Mol Carcinog 2005;44:122-136.
14. Kuver R, Savard C, Nguyen TD, Osborne WR, Lee SP. Isolation and long-term culture of gallbladder epithelial cells from wild type and CF mice. In Vitro Cell Dev Biol Anim 1997;33:104-109.
15. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006;57:647-653.
16. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-3993.
17. Scott GK, Marden C, Xu F, Kirk L, Benz CC. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol Cancer Ther 2002;1:385-392.
18. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528.
19. Price-Schiavi SA, Andrechek E, Idris N, Li P, Rong M, Zhang J, et al. Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy. J Cell Physiol 2005;203:44-53.
20. Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA. Cell signaling through membrane mucins. Bioessays 2003;25:66-71.
21. Vincent A, Ducourouble MP, Van Seuningen I. Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases. FASEB J 2008;22:3035-3045.
22. Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, et al. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci 2010;101:355-362.
23. Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 2007;27:5105-5119.
24. Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002;137:69-73.
25. Konstantinidis IT, Deshpande V, Genevay M, Berger D, Fernandez-del Castillo C, Tanabe KK, et al. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg 2009;144:441-447, discussion 447.
26. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008;49:502-507.
27. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-269.
28. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130: 2113-2129.
29. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, et al. MiR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004;1:106-113.
30. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322:1695-1699.